DK1054680T3 - Behandling af blærecancer med mycobacterium phlei cellevæg - Google Patents

Behandling af blærecancer med mycobacterium phlei cellevæg

Info

Publication number
DK1054680T3
DK1054680T3 DK98962163T DK98962163T DK1054680T3 DK 1054680 T3 DK1054680 T3 DK 1054680T3 DK 98962163 T DK98962163 T DK 98962163T DK 98962163 T DK98962163 T DK 98962163T DK 1054680 T3 DK1054680 T3 DK 1054680T3
Authority
DK
Denmark
Prior art keywords
cell wall
treatment
phlei
bladder cancer
phlei cell
Prior art date
Application number
DK98962163T
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of DK1054680T3 publication Critical patent/DK1054680T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98962163T 1998-02-18 1998-12-22 Behandling af blærecancer med mycobacterium phlei cellevæg DK1054680T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7511198P 1998-02-18 1998-02-18
PCT/CA1998/001190 WO1999042113A1 (en) 1998-02-18 1998-12-22 Composition and method for the treatment of bladder cancer
EP98962163A EP1054680B1 (en) 1998-02-18 1998-12-22 Treatment of bladder cancer by mycobacterium phlei cell wall

Publications (1)

Publication Number Publication Date
DK1054680T3 true DK1054680T3 (da) 2005-06-27

Family

ID=22123625

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98962163T DK1054680T3 (da) 1998-02-18 1998-12-22 Behandling af blærecancer med mycobacterium phlei cellevæg

Country Status (13)

Country Link
EP (1) EP1054680B1 (da)
JP (1) JP4426097B2 (da)
CN (1) CN1153576C (da)
AT (1) ATE290390T1 (da)
AU (1) AU751667B2 (da)
CA (1) CA2321296A1 (da)
DE (1) DE69829316T2 (da)
DK (1) DK1054680T3 (da)
ES (1) ES2238780T3 (da)
NZ (1) NZ506406A (da)
PT (1) PT1054680E (da)
RO (1) RO122992B1 (da)
WO (1) WO1999042113A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1181304E (pt) 1999-04-08 2008-01-23 Antisoma Res Ltd Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina
WO2001022979A1 (en) * 1999-09-29 2001-04-05 Bioniche Life Sciences Inc. Method to disrupt mitochondrial function
US7125858B2 (en) 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
CN101829154B (zh) * 2010-04-23 2012-12-26 广西医科大学第一附属医院 防治哮喘的药物组合物的制备方法
WO2012049654A1 (en) 2010-10-13 2012-04-19 Bioniche Life Sciences, Inc. Bacterial ribonucleic acid cell wall compositions and methods of making and using them
TR201101874A2 (tr) 2011-02-25 2011-08-22 Leyla A�An Nac�Ye Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법

Also Published As

Publication number Publication date
ES2238780T3 (es) 2005-09-01
HK1030887A1 (en) 2001-05-25
AU1746599A (en) 1999-09-06
NZ506406A (en) 2002-11-26
JP4426097B2 (ja) 2010-03-03
RO122992B1 (ro) 2010-06-30
EP1054680B1 (en) 2005-03-09
ATE290390T1 (de) 2005-03-15
DE69829316T2 (de) 2006-04-13
CN1290171A (zh) 2001-04-04
PT1054680E (pt) 2005-06-30
CA2321296A1 (en) 1999-08-26
JP2002503697A (ja) 2002-02-05
CN1153576C (zh) 2004-06-16
EP1054680A1 (en) 2000-11-29
DE69829316D1 (de) 2005-04-14
WO1999042113A1 (en) 1999-08-26
AU751667B2 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
DK0762898T3 (da) Cyclodextrinsystem til levering af oligonukleotider til celler
DK1082410T3 (da) Humane CD45 - og/eller fibroblast mesenchymale stamceller
BR0015110A (pt) Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
CA2291065A1 (en) Raf kinase inhibitors
PT1242060E (pt) Tratamento da doenca metastatica
PT1112275E (pt) Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
RU96102402A (ru) Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
AU2904300A (en) Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
WO2001006990A3 (en) Use of etodolac to treat cancer
DE60116642D1 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
AU2290000A (en) Phenanthridine-n-oxides with pde-iv inhibiting activity
PT1054680E (pt) Tratamento do cancro da bexiga pela parede celular de mycobacterium phlei
MY121046A (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
AU2107700A (en) Phenanthridine-n-oxides with pde-iv inhibiting activity
TR200102837T2 (tr) ídrar tutamama durumunun tedavisi
IL134371A0 (en) Composition and method for regulating cell proliferation and cell death
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
ATE307797T1 (de) Aktivierte iod-verbindungen zur behandlung von krebs und aids
HUP9904669A2 (hu) A T-BAM(CD40L)technológia terápiás alkalmazása simaizomsejtekkel kapcsolatos betegségek kezelésére
EP1165106B8 (en) Composition and method for inducing apoptosis in prostate cancer cells by m-dna and mcc
DK1135164T3 (da) Sammensætning til behandling af inflammation
DE69734690D1 (de) Monoklonaler Antikörper gegen Fibroblasten-Wachstumsfaktor-8
NO20012569L (no) Anvendelse av aryl-substituerte syklobutylalkylaminer for behandling av urininkontinens
EP1462113A4 (en) CELL GROWTH INHIBITORS WITH ANTI-PEPT ANTIBODIES